FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103455702> ?p ?o ?g. }

• W2103455702 endingPage "920" @default.
• W2103455702 startingPage "914" @default.
• W2103455702 abstract "In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.BackgroundWe investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer.Patients and methodsA candidate array was designed based on the Breast Cancer Information Core database for BRCA mutation analyses. An exploratory analysis of BRCA1/XPG mutation status was conducted using a two-sided log-rank test and 0.05 significance in germline DNA samples from 264 women with failed first-line platinum-based chemotherapy, randomized (1 : 1) to trabectedin + PLD or PLD alone.ResultsOverall, 41 (16%) of the 264 women had BRCA1mut (trabectedin + PLD: n = 24/135, 18%; PLD: n = 17/129; 13%) and 17 (6%) had XPGmut (trabectedin + PLD: n = 8/135, 6%; PLD: n = 9/129, 7%). A higher RR was observed in BRCA1mut patients (20/41; 49%) versus BRCA1wt patients (62/223; 28%). Within the BRCA1mut group, trabectedin + PLD-treated patients had longer PFS and longer OS than PLD-treated patients (median PFS 13.5 versus 5.5 months, P = 0.0002; median OS 23.8 versus 12.5 months, P = 0.0086), whereas in BRCA1wt patients, OS was not significantly different (median OS: 19.1 versus 19.3 months; P = 0.9377). There were no differences in OS or PFS of patients with XPGmut between the two treatment arms. However, trabectedin + PLD-treated patients with XPGmut had a trend toward shorter PFS (median PFS: 1.9 versus 7.5 months; P = 0.1666) and OS (median OS: 14.5 versus 20.7 months; P = 0.1774) than those with XPGwt.ConclusionsIn this exploratory analysis, patients with recurrent ovarian cancer carrying the BRCA1mut had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients." @default.
• W2103455702 created "2016-06-24" @default.
• W2103455702 creator A5000448920 @default.
• W2103455702 creator A5000978310 @default.
• W2103455702 creator A5022012567 @default.
• W2103455702 creator A5035411598 @default.
• W2103455702 creator A5042316451 @default.
• W2103455702 creator A5044874564 @default.
• W2103455702 creator A5056796582 @default.
• W2103455702 creator A5062165630 @default.
• W2103455702 creator A5066396938 @default.
• W2103455702 creator A5069247141 @default.
• W2103455702 creator A5077016336 @default.
• W2103455702 creator A5080782271 @default.
• W2103455702 creator A5086185159 @default.
• W2103455702 date "2015-05-01" @default.
• W2103455702 modified "2023-09-28" @default.
• W2103455702 title "Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study" @default.
• W2103455702 cites W2020830322 @default.
• W2103455702 cites W2077419786 @default.
• W2103455702 cites W2085076399 @default.
• W2103455702 cites W2096616470 @default.
• W2103455702 cites W2102004732 @default.
• W2103455702 cites W2116234966 @default.
• W2103455702 cites W2125064537 @default.
• W2103455702 cites W2139248078 @default.
• W2103455702 cites W2142795777 @default.
• W2103455702 cites W2149067734 @default.
• W2103455702 cites W2152214163 @default.
• W2103455702 cites W2160466424 @default.
• W2103455702 cites W2168839110 @default.
• W2103455702 cites W2246859176 @default.
• W2103455702 cites W2601189063 @default.
• W2103455702 doi "https://doi.org/10.1093/annonc/mdv071" @default.
• W2103455702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25722380" @default.
• W2103455702 hasPublicationYear "2015" @default.
• W2103455702 type Work @default.
• W2103455702 sameAs 2103455702 @default.
• W2103455702 citedByCount "55" @default.
• W2103455702 countsByYear W21034557022015 @default.
• W2103455702 countsByYear W21034557022016 @default.
• W2103455702 countsByYear W21034557022017 @default.
• W2103455702 countsByYear W21034557022018 @default.
• W2103455702 countsByYear W21034557022019 @default.
• W2103455702 countsByYear W21034557022020 @default.
• W2103455702 countsByYear W21034557022021 @default.
• W2103455702 countsByYear W21034557022022 @default.
• W2103455702 countsByYear W21034557022023 @default.
• W2103455702 crossrefType "journal-article" @default.
• W2103455702 hasAuthorship W2103455702A5000448920 @default.
• W2103455702 hasAuthorship W2103455702A5000978310 @default.
• W2103455702 hasAuthorship W2103455702A5022012567 @default.
• W2103455702 hasAuthorship W2103455702A5035411598 @default.
• W2103455702 hasAuthorship W2103455702A5042316451 @default.
• W2103455702 hasAuthorship W2103455702A5044874564 @default.
• W2103455702 hasAuthorship W2103455702A5056796582 @default.
• W2103455702 hasAuthorship W2103455702A5062165630 @default.
• W2103455702 hasAuthorship W2103455702A5066396938 @default.
• W2103455702 hasAuthorship W2103455702A5069247141 @default.
• W2103455702 hasAuthorship W2103455702A5077016336 @default.
• W2103455702 hasAuthorship W2103455702A5080782271 @default.
• W2103455702 hasAuthorship W2103455702A5086185159 @default.
• W2103455702 hasBestOaLocation W21034557021 @default.
• W2103455702 hasConcept C121608353 @default.
• W2103455702 hasConcept C126322002 @default.
• W2103455702 hasConcept C142724271 @default.
• W2103455702 hasConcept C143998085 @default.
• W2103455702 hasConcept C2776694085 @default.
• W2103455702 hasConcept C2778256501 @default.
• W2103455702 hasConcept C2778629024 @default.
• W2103455702 hasConcept C2780194787 @default.
• W2103455702 hasConcept C2780427987 @default.
• W2103455702 hasConcept C2780752271 @default.
• W2103455702 hasConcept C31760486 @default.
• W2103455702 hasConcept C71924100 @default.
• W2103455702 hasConceptScore W2103455702C121608353 @default.
• W2103455702 hasConceptScore W2103455702C126322002 @default.
• W2103455702 hasConceptScore W2103455702C142724271 @default.
• W2103455702 hasConceptScore W2103455702C143998085 @default.
• W2103455702 hasConceptScore W2103455702C2776694085 @default.
• W2103455702 hasConceptScore W2103455702C2778256501 @default.
• W2103455702 hasConceptScore W2103455702C2778629024 @default.
• W2103455702 hasConceptScore W2103455702C2780194787 @default.
• W2103455702 hasConceptScore W2103455702C2780427987 @default.
• W2103455702 hasConceptScore W2103455702C2780752271 @default.
• W2103455702 hasConceptScore W2103455702C31760486 @default.
• W2103455702 hasConceptScore W2103455702C71924100 @default.
• W2103455702 hasIssue "5" @default.
• W2103455702 hasLocation W21034557021 @default.
• W2103455702 hasLocation W21034557022 @default.
• W2103455702 hasOpenAccess W2103455702 @default.
• W2103455702 hasPrimaryLocation W21034557021 @default.
• W2103455702 hasRelatedWork W1967715255 @default.
• W2103455702 hasRelatedWork W2035720595 @default.
• W2103455702 hasRelatedWork W2057243137 @default.
• W2103455702 hasRelatedWork W2090090730 @default.
• W2103455702 hasRelatedWork W2096253955 @default.
• W2103455702 hasRelatedWork W2103455702 @default.

• next